Novavax (NASDAQ:NVAX) target price lowered to $1.00, reported today by Piperjaffray
- Updated: September 16, 2016
Indicating a possible downside of -0.28%, Piperjaffray dropped the target stock price of Novavax (NASDAQ:NVAX) to $1.
Previously on Tuesday August 23 2016, Vetr Inc. released a statement for Novavax(NASDAQ:NVAX) upped the target price from $0.00 to $8.66. At the time, this indicated a possible upside of 0.17%.
Boasting a price of $1.39, Novavax (NASDAQ:NVAX) traded 0.36% higher on the day. With the last stock price down 33.70% relative to the two hundred day average, compared to the Standard & Poor’s 500 Index which has decreased -0.01% over the same period. NVAX has logged a 50-day moving average of $7.35 and 200-day average of $6.24. Volume of trade was was up over the average, with 25,965,663 shares of NVAX changing hands over the typical 5,016,980 shares.
Novavax has a 52 week low of $4.08 and a one-year high of $10.70 and has a market capitalization of $0.0.
A total of 8 brokerages have reported on NVAX. Five firms rate the stock a strong buy, three firms rate the stock a buy, 0 analysts rate the stock a hold, 0 rate the stock to underperform, and lastly 0 firmsrate the company as sell with an average target of $15.39
Brief Synopsis About Novavax (NASDAQ:NVAX)
Novavax, Inc. (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. Its product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). Its lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, and including Middle East respiratory syndrome (MERS).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.